EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 6.9

Change

+0.02 (+0.29)%

Market Cap

N/A

Volume

1.60M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.77 (+0.39%)

USD 83.17B
HLN Haleon plc

-0.10 (-0.94%)

USD 47.33B
TAK Takeda Pharmaceutical Co Ltd A..

-0.03 (-0.20%)

USD 46.60B
RDY Dr. Reddy’s Laboratories Ltd..

-0.74 (-0.93%)

USD 13.37B
CTLT Catalent Inc

-0.03 (-0.05%)

USD 10.83B
ELAN Elanco Animal Health

+0.36 (+2.52%)

USD 7.15B
BHC Bausch Health Companies Inc

+0.84 (+11.70%)

USD 2.95B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.12 (-1.36%)

USD 2.70B
CPHI China Pharma Holdings Inc

N/A

USD 3.94M
YCBD cbdMD Inc

-0.05 (-9.23%)

USD 1.92M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 21.78 % 0.00 %

N/A

USD 0.05B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 21.78 % 0.00 %

+0.19 (+-0.18%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 21.35 % 0.00 %

+0.07 (+-0.18%)

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.01 % 0.00 %

-0.21 (-0.18%)

CAD 3.36M
IVES Amplify ETF Trust 3.94 % 0.00 %

-0.33 (-0.18%)

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

-0.08 (-0.18%)

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

N/A

USD 0.13B
LGGE:XETRA L&G Quality Equity Divide.. 1.38 % 0.00 %

-0.02 (-0.18%)

USD 0.03B
LDEU:LSE L&G Quality Equity Divide.. 1.37 % 0.00 %

N/A

USD 0.04B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

-4.40 (-0.18%)

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.97 % 0.00 %

+0.02 (+-0.18%)

USD 0.02B
PRFZ Invesco FTSE RAFI US 1500.. 0.28 % 0.39 %

-0.08 (-0.18%)

USD 2.45B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.16 (+-0.18%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 187.50% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 187.50% 100% F 100% F
Trailing 12 Months  
Capital Gain 89.04% 93% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.04% 93% A 97% N/A
Trailing 5 Years  
Capital Gain -86.49% 21% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.49% 21% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -34.50% 6% D- 1% F
Dividend Return -34.50% 6% D- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.71% 31% F 15% F
Risk Adjusted Return -61.93% 13% F 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector